US 11,684,606 B2
Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
James J. Campbell, San Jose, CA (US); Karen Ebsworth, San Francisco, CA (US); Antoni Krasinski, Sunnyvale, CA (US); Venkat Reddy Mali, Cupertino, CA (US); Jeffrey McMahon, San Francisco, CA (US); Rajinder Singh, Belmont, CA (US); Ju Yang, Palo Alto, CA (US); Chao Yu, Sunnyvale, CA (US); and Penglie Zhang, Foster City, CA (US)
Assigned to CHEMOCENTRYX, INC., Thousand Oaks, CA (US)
Filed by CHEMOCENTRYX, INC., San Carlos, CA (US)
Filed on Nov. 16, 2021, as Appl. No. 17/527,939.
Application 17/527,939 is a continuation of application No. 16/241,469, filed on Jan. 7, 2019, granted, now 11,207,294.
Claims priority of provisional application 62/715,503, filed on Aug. 7, 2018.
Claims priority of provisional application 62/614,927, filed on Jan. 8, 2018.
Prior Publication US 2022/0280481 A1, Sep. 8, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4035 (2006.01); A61P 29/00 (2006.01); A61P 17/06 (2006.01)
CPC A61K 31/4035 (2013.01) [A61P 17/06 (2018.01); A61P 29/00 (2018.01)] 15 Claims
 
1. A method of treating generalized pustular psoriasis (GPP) in a subject in need thereof, said method comprising administering to the subject an effective amount of a compound of Formula (A1)

OG Complex Work Unit Chemistry
wherein
R1a is selected from CH3 and Cl;
R1b is H or CH3;
R3 is H or D;
R4 is H;
R5a and R5b are each independently selected from H, F, Cl, Br and CH3;
R6a and R6b are each independently selected from H and CH3; and
R7 is methyl or ethyl; or
a pharmaceutically acceptable salt, solvate or hydrate, thereof.